Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer von R. Riera-Sala, A. Ibarra-Morales, J. Guzmán-Casta, R. Medrano-Guzmán, A. Dip-Borunda, A. Martin-Aguilar, R. Grajales-Álvarez, R. Correa-Cano, K. Elvira-Fabián, C. Sánchez-Ríos, A. Orzuna-Vázquez, J. Rovelo-Lima, L. Martínez-Barrera, J. Rodríguez-Cid, J. Alatorre-Alexander

Volltext

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer von Paz-Ares, Luis, Luft, Alexander, Vicente, David, Tafreshi, Ali, Gümüş, Mahmut, Mazières, Julien, Hermes, Barbara, Çay Şenler, Filiz, Csőszi, Tibor, Fülöp, Andrea, Rodríguez-Cid, Jerónimo, Wilson, Jonathan, Sugawara, Shunichi, Kato, Terufumi, Lee, Ki Hyeong, Cheng, Ying, Novello, Silvia, Halmos, Balazs, Li, Xiaodong, Lubiniecki, Gregory M, Piperdi, Bilal, Kowalski, Dariusz M

Volltext

Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: Data from KEYNOTE-... von Mazières, J., Kowalski, D., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Laktionov, K., Hermes, B., Cicin, I., Rodríguez-Cid, J., Wilson, J., Kato, T., Ramlau, R., Novello, S., Reddy, S., Piperdi, B., Li, X., Burke, T., Paz-Ares, L.

Volltext

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOS... von Felip, E., Cho, B.C., Gutiérrez, V., Alip, A., Besse, B., Lu, S., Spira, A.I., Girard, N., Califano, R., Gadgeel, S.M., Yang, J.C.-H., Yamamoto, S., Azuma, K., Kim, Y.J., Lee, K.-H., Danchaivijitr, P., Ferreira, C.G., Cheng, Y., Sendur, M.A.N., Chang, G.-C., Wang, C.-C., Prabhash, K., Shinno, Y., Stroyakovskiy, D., Paz-Ares, L., Rodriguez-Cid, J.R., Martin, C., Campelo, M.R.G., Hayashi, H., Nguyen, D., Tomasini, P., Gottfried, M., Dooms, C., Passaro, A., Schuler, M., Gelatti, A.C.Z., Owen, S., Perdrizet, K., Ou, S.-H.I., Curtin, J.C., Zhang, J., Gormley, M., Sun, T., Panchal, A., Ennis, M., Fennema, E., Daksh, M., Sethi, S., Bauml, J.M., Lee, S.-H.

Volltext

Digital Retinal Images and Teleophthalmology for Detecting and Grading Diabetic Retinopathy von GOMEZ-ULLA, Francisco, FERNANDEZ, Maria I, GONZALEZ, Francisco, REY, Pablo, RODRIGUEZ, Marta, RODRIGUEZ-CID, Maria J, CASANUEVA, Felipe F, TOME, Maria A, GARCIA-TOBIO, Javier, GUDE, Francisco

Volltext

Do Not Do» recommendations for retinopathies: A mixed consensus study von Pablo, L, Beckford, C A, Martin-Delgado, J, Ferro Osuna, M, Fernández-Ferreiro, A, Fernández Rodriguez, M I, Rodríguez Cid, M J, Méndez, S, Torres, A, Ignacio, E, Mira, J J

Volltext

Clinical features, management and outcomes of patients with sterile endophthalmitis associated with intravitreal injection of antivascular endothelial growth factor von Gil-Martínez, M, Rodríguez-Cid, M J, Fenández-Rodríguez, M I, Blanco-Teijero, M J, Abraldes, M J, Bandín Vilar, E, Zarra-Ferro, I, González-Barcia, M, Gómez-Ulla, F, Fernández-Ferreiro, A

Volltext

Do Not Do» recommendations for retinopathies: A mixed consensus study von Pablo, L., Beckford, C.A., Martin-Delgado, J., Ferro Osuna, M., Fernández-Ferreiro, A., Fernández Rodriguez, M.I., Rodriguez Cid, M.J., Méndez, S., Torres, A., Ignacio, E., Mira, J.J.

Volltext

Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L... von Owonikoko, T.K., Kim, H.R., Govindan, R., Ready, N., Reck, M., Peters, S., Dakhil, S.R., Navarro, A., Rodriguez-Cid, J., Schenker, M., Lee, J.S., Gutierrez, V., Percent, I., Morgensztern, D., Fairchild, J., Baudelet, C., Park, K.

Volltext

Further development of forensic eye color predictive tests von Ruiz, Y, Phillips, C, Gomez-Tato, A, Alvarez-Dios, J, Casares de Cal, M, Cruz, R, Maroñas, O, Söchtig, J, Fondevila, M, Rodriguez-Cid, M.J, Carracedo, Á, Lareu, M.V

Volltext

97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407 von Robinson, A.G., Vicente, D., Tafreshi, A., Parra, H. Soto, Mazieres, J., Cicin, I., Medgyasszay, B., Rodríguez-Cid, J., Okamoto, I., Lee, S., Ramlau, R., Vladimirov, V., Cheng, Y., Halmos, B., Liu, C-C., Schwarzenberger, P., Piperdi, B., Paz-Ares, L.

Volltext

1483PDPembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407 von Powell, S F, Abreu, D Rodriguez, Langer, C J, Tafreshi, A, Paz-Ares, L, Kopp, H-G, Rodríguez-Cid, J, Kowalski, D, Cheng, Y, Kurata, T, Awad, M M, Lin, J, Zhao, B, Pietanza, M C, Piperdi, B, Garassino, M C

Volltext

1483PD - Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407 von Powell, S.F., Abreu, D Rodriguez, Langer, C.J., Tafreshi, A., Paz-Ares, L., Kopp, H.-G., Rodríguez-Cid, J., Kowalski, D., Cheng, Y., Kurata, T., Awad, M.M., Lin, J., Zhao, B., Pietanza, M.C., Piperdi, B., Garassino, M.C.

Volltext

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407 von Powell, S.F., Abreu, D Rodriguez, Langer, C.J., Tafreshi, A., Paz-Ares, L., Kopp, H.-G., Rodríguez-Cid, J., Kowalski, D., Cheng, Y., Kurata, T., Awad, M.M., Lin, J., Zhao, B., Pietanza, M.C., Piperdi, B., Garassino, M.C.

Volltext

LBA62Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: Data from KEY... von Mazières, J, Kowalski, D, Luft, A, Vicente, D, Tafreshi, A, Gümüş, M, Laktionov, K, Hermes, B, Cicin, I, Rodríguez-Cid, J, Wilson, J, Kato, T, Ramlau, R, Novello, S, Reddy, S, Piperdi, B, Li, X, Burke, T, Paz-Ares, L

Volltext

Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407 von Paz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Soto Parra, H., Mazières, J., Hermes, B., Cicin, I., Medgyasszay, B., Beatrix, B., Rodríguez Cid, J., Okamoto, I., Lee, S., Ramlau, R., Vladimirov, V., Cheng, Y., Deng, X., Bas, T., Piperdi, B., Halmos, B.

Volltext

LBA82Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407 von Paz-Ares, L, Vicente, D, Tafreshi, A, Robinson, A, Soto Parra, H, Mazières, J, Hermes, B, Cicin, I, Medgyasszay, B, Beatrix, B, Rodríguez Cid, J, Okamoto, I, Lee, S, Ramlau, R, Vladimirov, V, Cheng, Y, Deng, X, Bas, T, Piperdi, B, Halmos, B

Volltext

LBA82 - Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407 von Paz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Soto Parra, H., Mazières, J., Hermes, B., Cicin, I., Medgyasszay, B., Beatrix, B., Rodríguez Cid, J., Okamoto, I., Lee, S., Ramlau, R., Vladimirov, V., Cheng, Y., Deng, X., Bas, T., Piperdi, B., Halmos, B.

Volltext

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer von Peters, Solange, Camidge, D. Ross, Shaw, Alice T, Gadgeel, Shirish, Ahn, Jin S, Kim, Dong-Wan, Ou, Sai-Hong I, Pérol, Maurice, Dziadziuszko, Rafal, Rosell, Rafael, Zeaiter, Ali, Mitry, Emmanuel, Golding, Sophie, Balas, Bogdana, Noe, Johannes, Morcos, Peter N, Mok, Tony

Volltext

Prevalence of metabolic syndrome (MS) in laboral population. The heart of Asepeyo von Gutiérrez Guisado, J, López Manzano, J J, Rodríguez Cid, J, Garcés Segura, C, Llorens Rufach, M T

Volltext